EP3914265A4 - B cell immunotherapy - Google Patents

B cell immunotherapy Download PDF

Info

Publication number
EP3914265A4
EP3914265A4 EP20745872.0A EP20745872A EP3914265A4 EP 3914265 A4 EP3914265 A4 EP 3914265A4 EP 20745872 A EP20745872 A EP 20745872A EP 3914265 A4 EP3914265 A4 EP 3914265A4
Authority
EP
European Patent Office
Prior art keywords
cell immunotherapy
immunotherapy
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20745872.0A
Other languages
German (de)
French (fr)
Other versions
EP3914265A1 (en
Inventor
Mark C. Poznansky
Ruxandra F. SIRBULESCU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Holy Cross Hospital Inc
Original Assignee
General Hospital Corp
Holy Cross Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Holy Cross Hospital Inc filed Critical General Hospital Corp
Priority claimed from PCT/US2020/014836 external-priority patent/WO2020154534A1/en
Publication of EP3914265A1 publication Critical patent/EP3914265A1/en
Publication of EP3914265A4 publication Critical patent/EP3914265A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20745872.0A 2019-01-23 2020-01-23 B cell immunotherapy Pending EP3914265A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795629P 2019-01-23 2019-01-23
US201962837765P 2019-04-24 2019-04-24
PCT/US2020/014836 WO2020154534A1 (en) 2019-01-23 2020-01-23 B cell immunotherapy

Publications (2)

Publication Number Publication Date
EP3914265A1 EP3914265A1 (en) 2021-12-01
EP3914265A4 true EP3914265A4 (en) 2023-02-01

Family

ID=78232398

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20745872.0A Pending EP3914265A4 (en) 2019-01-23 2020-01-23 B cell immunotherapy

Country Status (2)

Country Link
EP (1) EP3914265A4 (en)
CN (1) CN113677354A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115393351B (en) * 2022-10-27 2023-01-24 北京大学第三医院（北京大学第三临床医学院） Method and device for judging cornea immune state based on Langerhans cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178613A1 (en) * 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060130649A (en) * 2004-02-09 2006-12-19 미츠비시 웰파마 가부시키가이샤 Novel therapeutic agent for amyotrophic lateral sclerosis(als) or disease attributable to als
WO2006113647A2 (en) * 2005-04-18 2006-10-26 Actx, Inc. Recovery of tissue function following administration of b cells to injured tissue
EP1901769A2 (en) * 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
CA2722184A1 (en) * 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
WO2011147622A1 (en) * 2010-05-26 2011-12-01 Deutsches Rheuma-Forschungszentrum Berlin Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178613A1 (en) * 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. RAY ET AL: "A Novel IL-10-Independent Regulatory Role for B Cells in Suppressing Autoimmunity by Maintenance of Regulatory T Cells via GITR Ligand", THE JOURNAL OF IMMUNOLOGY, vol. 188, no. 7, 1 April 2012 (2012-04-01), pages 3188 - 3198, XP055034451, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1103354 *
BODHANKAR SHEETAL ET AL: "IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke", METABOLIC BRAIN DISEASE, vol. 28, no. 3, 1 September 2013 (2013-09-01), US, pages 375 - 386, XP055960801, ISSN: 0885-7490, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s11011-013-9413-3.pdf> DOI: 10.1007/s11011-013-9413-3 *
MILO RON ET AL: "Therapies for multiple sclerosis targeting B cells", CROATIAN MEDICAL JOURNAL, vol. 60, no. 2, 1 April 2019 (2019-04-01), CR, pages 87 - 98, XP055960892, ISSN: 0353-9504, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509632/pdf/CroatMedJ_60_0087.pdf> DOI: 10.3325/cmj.2019.60.87 *
PENNATI ANDREA ET AL: "Adoptive transfer of IL-10+regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model", CELLULAR & MOLECULAR IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 15, no. 7, 8 January 2018 (2018-01-08), pages 727 - 730, XP036854777, ISSN: 1672-7681, [retrieved on 20180108], DOI: 10.1038/CMI.2017.152 *
See also references of WO2020154534A1 *

Also Published As

Publication number Publication date
CN113677354A (en) 2021-11-19
EP3914265A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
EP3817131A4 (en) Battery
EP3925297A4 (en) Primary cell change
EP3918048A4 (en) Flow cells
EP3949998A4 (en) Cell activator
EP3930031A4 (en) Battery
EP3961743A4 (en) Battery
EP3805270A4 (en) Improved anti-cd19 car-t cell
EP3780136A4 (en) Cell
EP3996179A4 (en) Battery
EP3823639A4 (en) Msc- and exosome-based immunotherapy
EP3918050A4 (en) Flow cells
EP3806894A4 (en) Plap-car-effector cells
EP3909590A4 (en) Cellular immunotherapy combination
EP3993798A4 (en) Novel methods
EP3893285A4 (en) Solar cell
EP3962955A4 (en) Antigen specific cd19-targeted car-t cells
EP4005327A4 (en) Techniques for cell selection for dual-connectivity
EP4007655A4 (en) Flow cells
EP4047694A4 (en) Battery
EP4034119A4 (en) Novel methods
EP4012832A4 (en) Battery
EP4018510A4 (en) Battery
EP3998660A4 (en) Battery
EP3951962A4 (en) Solid electrolyte
EP3958336A4 (en) Solar cell

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HOLY CROSS HOSPITAL, INC.

Owner name: THE GENERAL HOSPITAL CORPORATION

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0781 20100101ALI20220920BHEP

Ipc: A61P 25/28 20060101ALI20220920BHEP

Ipc: A61K 35/12 20150101AFI20220920BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230105

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0781 20100101ALI20221223BHEP

Ipc: A61P 25/28 20060101ALI20221223BHEP

Ipc: A61K 35/12 20150101AFI20221223BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240614

17Q First examination report despatched

Effective date: 20240626